Foundations of Evidence for the Use of BTK Inhibitors in B-Cell Malignancies and Management Strategies for Cardiac and Bleeding Adverse Effects

Educational Objectives:

At the completion of this activity, participants will be able to:

Outline the efficacy of oral BTK inhibitors across B-cell malignancies including a focus on emerging clinical data

Recognize pharmacists’ responsibilities for monitoring and managing cardiac adverse effects specific to different health-system practice types

Anthony J. Perissinotti, PharmD, BCOP is a Clinical Pharmacist Specialist, Hematology and the Clinical Team Leader Hematology/Oncology as well as an Adjunct Clinical Assistant Professor at the University of Michigan - Michigan Medicine in Ann Arbor, Michigan

He has no relevant financial relationships with commercial interests to disclose.

PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours of knowledge-based credit.

Click here to view the activity on the PTCE website and claim your credit: https://www.pharmacytimes.org/on-demand/bcell-malignancies-podcast-part1

This activity is supported by educational grants from Pharmacyclics LLC., an AbbVie Company and Janssen Biotech, Inc and Beigene.

See omnystudio.com/listener for privacy information.

Learn more about your ad choices. Visit megaphone.fm/adchoices